Form and function in cyclic peptide natural products: A pharmacokinetic perspective

Current Topics in Medicinal Chemistry

Volumn 13, Issue 6 7, 2013, Pages 821-836

  Bockus, Andrew T ^a   McEwen, Cayla M ^a   Scott Lokey, R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell permeability; Cyclic peptides; Cyclosporine A; Lipinski's rules; Pharmacokinetics

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; ARGYRIN B; AUREOBASIDIN A; BACTENECIN; CALCINEURIN; CYCLOMARIN 33; CYCLOMARIN A; CYCLOPEPTIDE; CYCLOPHILIN; CYCLOSPORIN A; CYCLOTIDE; CYTOCHROME P450; DESTRUXIN; DIDEMNIN B; DOUBLE STRANDED DNA; G PROTEIN COUPLED RECEPTOR; GRAMICIDIN S; GUANGOMIDE A; LUZOPEPTIN; NONRIBOSOMAL PEPTIDE SYNTHETASE; OXAZOLE DERIVATIVE; POLYMYXIN B; POTASSIUM CHANNEL; TACHYPLESIN; THIAZOLE DERIVATIVE; THIOSTREPTON; UNCLASSIFIED DRUG; VALINOMYCIN; YM 254890;

ANTIMICROBIAL ACTIVITY; CELL MEMBRANE PERMEABILITY; CRYSTAL STRUCTURE; CYCLIZATION; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; METHYLATION; NUCLEAR MAGNETIC RESONANCE; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; T LYMPHOCYTE ACTIVATION; X RAY CRYSTALLOGRAPHY;

EID: 84878789554     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313070005     Document Type: Review

References (136)

1. Luo, B.; Cheung, H. W.; Subramanian, A.; Sharifnia, T.; Okamoto, M.; Yang, X.; Hinkle, G.; Boehm, J. S.; Beroukhim, R.; Weir, B. A.; Mermel, C.; Barbie, D. A.; Awad, T.; Zhou, X.; Nguyen, T.; Piqani, B.; Li, C.; Golub, T. R.; Meyerson, M.; Hacohen, N.; Hahn, W. C.; Lander, E. S.; Sabatini, D. M.; Root, D. E., Highly parallel identification of essential genes in cancer cells. Proc. Natl. Acad. Sci. U. S. A., 2008, 105 (51), 20380-5.
2. Hur, G. H.; Vickery, C. R.; Burkart, M. D., Explorations of cata-lytic domains in non-ribosomal peptide synthetase enzymology. Nat. Prod. Rep., 2012.
3. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Ex-perimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46 (1-3), 3-26.
4. Lipinski, C. A., Drug-like properties and the causes of poor solubil-ity and poor permeability. J. Pharmacol. Toxicol. Methods, 2000, 44 (1), 235-49.
5. Kwan, K. C., Oral bioavailability and first-pass effects. Drug Met.Disp., 1997, 25 (12), 1329-36.
6. Lewis, D. F.; Dickins, M., Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobi-otic-metabolizing hepatic microsomal P450s. Toxicology, 2002, 170 (1-2), 45-53.
7. Lewis, D. F., Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology, 2000, 144 (1-3), 197-203.
8. Rezai, T.; Yu, B.; Millhauser, G. L.; Jacobson, M. P.; Lokey, R. S., Testing the Conformational Hypothesis of Passive Membrane Permeability Using Synthetic Cyclic Peptide Diastereomers. J. Am. Chem. Soc., 2006, 128, 2510-2511.
9. Gentilucci, L.; De Marco, R.; Cerisoli, L., Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des., 2010, 16 (28), 3185-203.
10. Delorbe, J. E.; Clements, J. H.; Whiddon, B. B.; Martin, S. F., Thermodynamic and Structural Effects of Macrocyclization as a Constraining Method in Protein-Ligand Interactions. ACS Med. Chem. Lett., 2010, 1 (8), 448-452.
11. DeLorbe, J. E.; Clements, J. H.; Teresk, M. G.; Benfield, A. P.; Plake, H. R.; Millspaugh, L. E.; Martin, S. F., Thermodynamic and structural effects of conformational constraints in protein-ligand interactions. Entropic paradoxy associated with ligand preorganiza-tion. J. Am. Chem. Soc., 2009, 131 (46), 16758-70.
12. Hancock, R. E.; Scott, M. G., The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. U. S. A., 2000, 97 (16), 8856-61.
13. Yeaman, M. R.; Yount, N. Y., Mechanisms of antimicrobial pep-tide action and resistance. Pharmacol. Rev., 2003, 55 (1), 27-55.
14. Zasloff, M., Antimicrobial peptides of multicellular organisms. Nature, 2002, 415 (6870), 389-95.
15. Augustijns, P. F.; Bradshaw, T. P.; Gan, L. S. L.; Hendren, R. W.; Thakker, D. R., Evidence for a Polarized Efflux System in Caco-2 Cells Capable of Modulating Cyclosporine-a Transport. Biochem. Biophys. Res. Commun., 1993, 197 (2), 360-365.
16. Rezai, T.; Bock, J. E.; Zhou, M. V.; Kalyanaraman, C.; Lokey, R. S.; Jacobson, M. P., Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc., 2006, 128 (43), 14073-80.
17. White, T. R.; Renzelman, C. M.; Rand, A. C.; Rezai, T.; McEwen, C. M.; Gelev, V. M.; Turner, R. A.; Linington, R. G.; Leung, S. S.; Kalgutkar, A. S.; Bauman, J. N.; Zhang, Y.; Liras, S.; Price, D. A.; Mathiowetz, A. M.; Jacobson, M. P.; Lokey, R. S., On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat. Chem. Biol., 2011, 7 (11), 810-7.
18. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D., Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45 (12), 2615-23.
19. Wilmot, C. M.; Thornton, J. M., Analysis and Prediction of the Different Types of b-Turn in Proteins. J. Mol. Biol., 1988, 203, 221-232.
20. Wilmot, C. M.; Thornton, J. M., Beta-turns and their distortions: a proposed new nomenclature. Protein Eng., 1990, 3 (6), 479-93.
21. Rose, G. D.; Gierasch, L. M.; Smith, J. A., Turns in Peptides and Proteins. In Adv. Protein Chem., Anfinsen, C. B., Ed. Academic Press: Orlando, FL, 1985; Vol. 37, pp 1-97.
22. Chatterjee, J.; Rechenmacher, F.; Kessler, H., N-methylation of peptides and proteins: an important element for modulating biological functions. Angew. Chem., 2013, 52 (1), 254-69.
23. Ovadia, O.; Greenberg, S.; Chatterjee, J.; Laufer, B.; Opperer, F.; Kessler, H.; Gilon, C.; Hoffman, A., The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Molecular pharmaceutics, 2011, 8 (2), 479-87.
24. Biron, E.; Chatterjee, J.; Ovadia, O.; Langenegger, D.; Brueggen, J.; Hoyer, D.; Schmid, H. A.; Jelinek, R.; Gilon, C.; Hoffman, A.; Kessler, H., Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew. Chem., 2008, 47 (14), 2595-9.
25. Beck, J. G.; Chatterjee, J.; Laufer, B.; Kiran, M. U.; Frank, A. O.; Neubauer, S.; Ovadia, O.; Greenberg, S.; Gilon, C.; Hoffman, A.; Kessler, H., Intestinal permeability of cyclic peptides: common key backbone motifs identified. J. Am. Chem. Soc., 2012, 134 (29), 12125-33.
26. Bock, J. E.; Gavenonis, J.; Kritzer, J. A., Getting in Shape: Controlling Peptide Bioactivity and Bioavailability Using Conformational Constraints. ACS Chem. Biol., 2012.
27. Schreiber, S. L.; Crabtree, G. R., The mechanism of action of cy-closporin A and FK506. Immunol. Today, 1992, 13 (4), 136-42.
28. Loosli, H. R.; Kessler, H.; Oschkinat, H.; Weber, H. P.; Petcher, T. J.; Widmer, A., Peptide conformations. Part 31. The conformation of cyclosporin A in the crystal and in solution. Helv. Chim. Acta, 1985, 68 (3), 682-704.
29. Kessler, H.; Kock, M.; Wein, T.; Gehrke, M., Reinvestigation of the Conformation of Cyclosporin A in Chloroform. Helv. Chim. Acta, 1990, 73, 1818-1832.
30. Jin, L.; Harrison, S. C., Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc. Natl. Acad. Sci. U. S. A., 2002, 99 (21), 13522-6.
31. Ko, S. Y.; Dalvit, C., Conformation of cyclosporin A in polar solvents. Int. J. Pept. Protein Res., 1992, 40 (5), 380-2.
32. Smith, G. D.; Duax, W. L.; Langs, D. A.; DeTitta, G. T.; Edmonds, J. W.; Rohrer, D. C.; Weeks, C. M., The crystal and molecular structure of the triclinic and monoclinic forms of valinomycin, C54H90N6O18. J. Am. Chem. Soc., 1975, 97 (25), 7242-7.
33. Hamilton, J. A.; Sabesan, M. N.; Steinrauf, L. K., Crystal structure of valinomycin potassium picrate: anion effects on valinomycin cation complexes. J. Am. Chem. Soc., 1981, 103 (19), 5880-5885.
34. Rose, M. C.; Henkens, R. W., Stability of Sodium and Potassium Complexes of Valinomycin. Biochim. Biophys. Acta, 1974, 372 (2), 426-435.
35. Crews, C. M.; Collins, J. L.; Lane, W. S.; Snapper, M. L.; Schrei-ber, S. L., GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. J. Biol. Chem., 1994, 269 (22), 15411-4.
36. Ahuja, D.; Vera, M. D.; SirDeshpande, B. V.; Morimoto, H.; Williams, P. G.; Joullie, M. M.; Toogood, P. L., Inhibition of protein synthesis by didemnin B: how EF-1alpha mediates inhibition of translocation. Biochemistry, 2000, 39 (15), 4339-46.
37. SirDeshpande, B. V.; Toogood, P. L., Mechanism of protein synthesis inhibition by didemnin B in vitro. Biochemistry, 1995, 34 (28), 9177-84.
38. Le Tourneau, C.; Faivre, S.; Ciruelos, E.; Dominguez, M. J.; Lopez-Martin, J. A.; Izquierdo, M. A.; Jimeno, J.; Raymond, E., Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. Am. J. Clin. Oncol., 2010, 33 (2), 132-6.
39. Mateos, M. V.; Cibeira, M. T.; Richardson, P. G.; Prosper, F.; Oriol, A.; de la Rubia, J.; Lahuerta, J. J.; Garcia-Sanz, R.; Extrem-era, S.; Szyldergemajn, S.; Corrado, C.; Singer, H.; Mitsiades, C. S.; Anderson, K. C.; Blade, J.; San Miguel, J., Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin. Cancer Res., 2010, 16 (12), 3260-9.
40. Brandon, E. F.; Sparidans, R. W.; van Ooijen, R. D.; Meijerman, I.; Lazaro, L. L.; Manzanares, I.; Beijnen, J. H.; Schellens, J. H., In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest. New Drugs, 2007, 25 (1), 9-19.
41. Faivre, S.; Chieze, S.; Delbaldo, C.; Ady-Vago, N.; Guzman, C.; Lopez-Lazaro, L.; Lozahic, S.; Jimeno, J.; Pico, F.; Armand, J. P.; Martin, J. A.; Raymond, E., Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J. Clin. Oncol., 2005, 23 (31), 7871-80.
42. Depenbrock, H.; Peter, R.; Faircloth, G. T.; Manzanares, I.; Jimeno, J.; Hanauske, A. R., In vitro activity of aplidine, a new ma-rine-derived anti-cancer compound, on freshly explanted clono-genic human tumour cells and haematopoietic precursor cells. Br. J. Cancer, 1998, 78 (6), 739-44.
43. Berer, N.; Rudi, A.; Goldberg, I.; Benayahu, Y.; Kashman, Y., Callynormine A, a new marine cyclic peptide of a novel class. Org. Lett., 2004, 6 (15), 2543-5.
44. Arnold, E.; Clardy, J., Crystal and molecular structure of BBM-928 A, a novel antitumor antibiotic from Actinomadura luzonensis. J. Am. Chem. Soc., 1981, 103 (5), 1243-1244.
45. Searle, M. S.; Hall, J. G.; Wakelin, P. G., 1H- and 13C-n.m.r. studies of the antitumour antibiotic luzopeptin. Resonance assignments, conformation and flexibility in solution. Biochem. J., 1988, 256 (1), 271-8.
46. Searle, M. S.; Hall, J. G.; Denny, W. A.; Wakelin, L. P., NMR studies of the interaction of the antibiotic nogalamycin with the hexadeoxyribonucleotide duplex d(5'-GCATGC)2. Biochemistry, 1988, 27 (12), 4340-9.
47. Zhang, X. L.; Patel, D. J., Solution structure of the luzopeptin-DNA complex. Biochemistry, 1991, 30 (16), 4026-41.
48. Taniguchi, M.; Nagai, K.; Arao, N.; Kawasaki, T.; Saito, T.; Mori-tani, Y.; Takasaki, J.; Hayashi, K.; Fujita, S.; Suzuki, K.; Tsuka-moto, S., YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666. J. Antibiotics, 2003, 56 (4), 358-63.
49. Nishimura, A.; Kitano, K.; Takasaki, J.; Taniguchi, M.; Mizuno, N.; Tago, K.; Hakoshima, T.; Itoh, H., Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc. Natl. Acad. Sci. U. S. A., 2010, 107 (31), 13666-71.
50. Miyamae, A.; Fujioka, M.; Koda, S.; Morimoto, Y., Structural studies of FR900359, a novel cyclic depsipeptide from Ardisia cre-nata sims(Myrsinaceae). J. Chem. Soc., Perkin Trans. 1, 1989, (5).
51. Augustijns, P. F.; Brown, S. C.; Willard, D. H.; Consler, T. G.; Annaert, P. P.; Hendren, R. W.; Bradshaw, T. P., Hydration changes implicated in the remarkable temperature-dependent membrane permeation of cyclosporin A. Biochemistry, 2000, 39 (25), 7621-30.
52. Leung, S. S.; Mijalkovic, J.; Borrelli, K.; Jacobson, M. P., Testing physical models of passive membrane permeation. J. Chem. Inf. Mod., 2012, 52 (6), 1621-36.
53. Seelig, A., The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J. Mol. Neurosci., 2007, 33 (1), 32-41.
54. Hawkins, C. J.; Lavin, M. F.; Marshall, K. A.; van den Brenk, A. L.; Watters, D. J., Structure-activity relationships of the lissoclina-mides: cytotoxic cyclic peptides from the ascidian Lissoclinum patella. J. Med. Chem., 1990, 33 (6), 1634-8.
55. Wipf, P.; Fritch, P. C.; Geib, S. J.; Sefler, A. M., Conformational studies and structure-activity analysis of lissoclinamide 7 and related cyclopeptide alkaloids. J. Am. Chem. Soc., 1998, 120 (17), 4105-4112.
56. Pettit, G. R.;J.-p.; Dorsaz, A.-C.; Williams, M. D.; Boyd, M. R.; Cerny, R. L., Isolation and structure of the human cancer cell growth inhibitory cyclic decapeptides phakellistatins 7, 8 and 91,2. Bioorg. Med. Chem. Lett., 1995, 5 (13), 1339-1344.
57. Pettit, G. R.; Rhodes, M. R.; Tan, R., Antineoplastic agents. 400. Synthesis of the Indian Ocean marine sponge cyclic heptapeptide phakellistatin 2. J. Nat. Prod., 1999, 62 (3), 409-14.
58. Pettit, G. R.; Toki, B. E.;J. P.; Brune, D. C., Synthesis of the marine sponge cycloheptapeptide phakellistatin 5(1). J. Nat. Prod., 2000, 63 (1), 22-8.
59. Cane, D. E.; Walsh, C. T., The parallel and convergent universes of polyketide synthases and nonribosomal peptide synthetases. Chem. Biol., 1999, 6 (12), R319-25.
60. Du, L.; Shen, B., Biosynthesis of hybrid peptide-polyketide natural products. Curr. Op. Drug Disc. Dev., 2001, 4 (2), 215-28.
61. Du, L.; Sanchez, C.; Shen, B., Hybrid peptide-polyketide natural products: biosynthesis and prospects toward engineering novel molecules. Metab. Eng., 2001, 3 (1), 78-95.
62. Luesch, H.; Yoshida, W. Y.; Moore, R. E.; Paul, V. J.; Corbett, T. H., Total structure determination of apratoxin A, a potent novel cy-totoxin from the marine cyanobacterium Lyngbya majuscula. J. Am. Chem. Soc., 2001, 123 (23), 5418-23.
63. Liu, Y.; Law, B. K.; Luesch, H., Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation. Mol. Pharmacol., 2009, 76 (1), 91-104.
64. Shen, S.; Zhang, P.; Lovchik, M. A.; Li, Y.; Tang, L.; Chen, Z.; Zeng, R.; Ma, D.; Yuan, J.; Yu, Q., Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagy. J. Cell Biol., 2009, 185 (4), 629-39.
65. Senderowicz, A. M.; Kaur, G.; Sainz, E.; Laing, C.; Inman, W. D.; Rodriguez, J.; Crews, P.; Malspeis, L.; Grever, M. R.; Sausville, E. A.; et al., Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. J. Natl. Cancer Inst., 1995, 87 (1), 46-51.
66. Odaka, C.; Sanders, M. L.; Crews, P., Jasplakinolide induces apop-tosis in various transformed cell lines by a caspase-3-like protease-dependent pathway. Clin. Diagn. Lab. Immunol., 2000, 7 (6), 947-52.
67. Bubb, M. R.; Spector, I.; Beyer, B. B.; Fosen, K. M., Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations. J. Biol. Chem., 2000, 275 (7), 5163-70.
68. Bubb, M. R.; Senderowicz, A. M.; Sausville, E. A.; Duncan, K. L.; Korn, E. D., Jasplakinolide, a cytotoxic natural product, induces ac-tin polymerization and competitively inhibits the binding of phal-loidin to F-actin. J. Biol. Chem., 1994, 269 (21), 14869-71.
69. Inman, W.; Crews, P., Novel Marine Sponge Derived Amino-Acids.8. Conformational-Analysis of Jasplakinolide. J. Am. Chem. Soc., 1989, 111 (8), 2822-2829.
70. Tabudravu, J. N.; Morris, L. A.; Milne, B. F.; Jaspars, M., Confor-mational studies of free and Li+ complexed jasplakinolide, a cyclic depsipeptide from the Fijian marine sponge Jaspis splendens. Org. Biomol. Chem., 2005, 3 (5), 745-749.
71. Milroy, L. G.; Rizzo, S.; Calderon, A.; Ellinger, B.; Erdmann, S.; Mondry, J.; Verveer, P.; Bastiaens, P.; Waldmann, H.; Dehmelt, L.; Arndt, H. D., Selective chemical imaging of static actin in live cells. J. Am. Chem. Soc., 2012, 134 (20), 8480-6.
72. Gao, J.; Hamann, M. T., Chemistry and biology of kahalalides. Chem. Rev., 2011, 111 (5), 3208-35.
73. Suarez, Y.; Gonzalez, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Munoz, A., Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol. Cancer Ther., 2003, 2 (9), 863-72.
74. Sewell, J. M.; Mayer, I.; Langdon, S. P.; Smyth, J. F.; Jodrell, D. I.; Guichard, S. M., The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines. Eur. J. Cancer, 2005, 41 (11), 1637-44.
75. Janmaat, M. L.; Rodriguez, J. A.; Jimeno, J.; Kruyt, F. A.; Giac-cone, G., Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol., 2005, 68 (2), 502-10.
76. Garcia-Rocha, M.; Bonay, P.; Avila, J., The antitumoral compound Kahalalide F acts on cell lysosomes. Cancer Lett., 1996, 99 (1), 43-50.
77. Piggott, A. M.; Karuso, P., Rapid identification of a protein binding partner for the marine natural product kahalalide F by using reverse chemical proteomics. Chembiochem, 2008, 9 (4), 524-30.
78. Hosta, L.; Pla-Roca, M.; Arbiol, J.; Lopez-Iglesias, C.; Samitier, J.; Cruz, L. J.; Kogan, M. J.; Albericio, F., Conjugation of Kahalalide F with gold nanoparticles to enhance in vitro antitumoral activity. Bioconjugate Chem., 2009, 20 (1), 138-46.
79. Sparidans, R. W.; Stokvis, E.; Jimeno, J. M.; Lopez-Lazaro, L.; Schellens, J. H.; Beijnen, J. H., Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F. Anticancer. Drugs, 2001, 12 (7), 575-82.
80. Rademaker-Lakhai, J. M.; Horenblas, S.; Meinhardt, W.; Stokvis, E.; de Reijke, T. M.; Jimeno, J. M.; Lopez-Lazaro, L.; Lopez Martin, J. A.; Beijnen, J. H.; Schellens, J. H., Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin. Cancer Res., 2005, 11 (5), 1854-62.
81. Beijnen, J. H.; Rademaker-Lakhai, J. M.; Horenblas, S.; Meinhardt, W.; Stokvis, E.; De Rijke, T. M.; Jimeno, J. M.; Lazaro, L. L.; Martin, J. A. L.; Schellens, J., Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer. J. Clin. Oncol., 2004, 22 (14), 146S-146S.
82. Schellens, J. H.; Rademaker, J. L.; Horenblas, S.; Meinhardt, W.; Stokvis, E.; De Reijke, T. M.; Jimeno, J. M.; Lazaro, L. L.; Martin, J. A. L.; Beijnen, J. H., Phase I and pharmacokinetic study of kaha-lalide F in patients with advanced androgen refractory prostate cancer. Clin. Cancer Res., 2001, 7 (11), 3694S-3694S.
83. Pardo, B.; Paz-Ares, L.; Tabernero, J.; Ciruelos, E.; Garcia, M.; Salazar, R.; Lopez, A.; Blanco, M.; Nieto, A.; Jimeno, J.; Izquierdo, M. A.; Trigo, J. M., Phase I clinical and pharmacoki-netic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin. Cancer Res., 2008, 14 (4), 1116-1123.
84. de Bruijn, I.; de Kock, M. J.; Yang, M.; de Waard, P.; van Beek, T. A.; Raaijmakers, J. M., Genome-based discovery, structure prediction and functional analysis of cyclic lipopeptide antibiotics in Pseudomonas species. Mol. Microbiol., 2007, 63 (2), 417-28.
85. Sinnaeve, D.; Hendrickx, P. M.; Van Hemel, J.; Peys, E.; Kieffer, B.; Martins, J. C., The solution structure and self-association properties of the cyclic lipodepsipeptide pseudodesmin A support its pore-forming potential. Chemistry, 2009, 15 (46), 12653-62.
86. Han, F.; Mortishire-Smith, R. J.; Rainey, P. B.; Williams, D. H., Structure of the white-line-inducing principle isolated from Pseu-domonas reactans. Acta Crystallogr. Sect. C: Cryst. Struct. Com-mun., 1992, 48 (11), 1965-1968.
87. Quail, J. W.; Ismail, N.; Pedras, M. S. C.; Boyetchko, S. M., Pseu-dophomins A and B, a class of cyclic lipodepsipeptides isolated from a Pseudomonas species. Acta Crystallogr. Sect. C: Cryst. Struct. Commun., 2002, 58 (5), o268-o271.
88. Sorensen, D.; Nielsen, T. H.; Christophersen, C.; Sorensen, J.; Gajhede, M., Cyclic lipoundecapeptide amphisin from Pseudo-monas sp. strain DSS73. Acta Crystallogr. Sect. C: Cryst. Struct. Commun., 2001, 57 (9), 1123-1124.
89. Henriksen, A.; Anthoni, U.; Nielsen, T. H.; Sorensen, J.; Christo-phersen, C.; Gajhede, M., Cyclic lipoundecapeptide tensin from Pseudomonas fluorescens strain 96.578. Acta Crystallogr. Sect. C: Cryst. Struct. Commun., 2000, 56 (1), 113-115.
90. Andjelic, C. D.; Planelles, V.; Barrows, L. R., Characterizing the anti-HIV activity of papuamide A. Marine drugs, 2008, 6 (4), 528-49.
91. Parsons, A. B.; Lopez, A.; Givoni, I. E.; Williams, D. E.; Gray, C. A.; Porter, J.; Chua, G.; Sopko, R.; Brost, R. L.; Ho, C. H.; Wang, J.; Ketela, T.; Brenner, C.; Brill, J. A.; Fernandez, G. E.; Lorenz, T. C.; Payne, G. S.; Ishihara, S.; Ohya, Y.; Andrews, B.; Hughes, T. R.; Frey, B. J.; Graham, T. R.; Andersen, R. J.; Boone, C., Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell, 2006, 126 (3), 611-25.
92. Harms, J. M.; Wilson, D. N.; Schluenzen, F.; Connell, S. R.; Stachelhaus, T.; Zaborowska, Z.; Spahn, C. M.; Fucini, P., Transla-tional regulation via L11: molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol. Cell, 2008, 30 (1), 26-38.
93. Radhakrishnan, S. K.; Bhat, U. G.; Hughes, D. E.; Wang, I. C.; Costa, R. H.; Gartel, A. L., Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res., 2006, 66 (19), 9731-5.
94. Nakano, I.; Joshi, K.; Visnyei, K.; Hu, B.; Watanabe, M.; Lam, D.; Wexler, E.; Saigusa, K.; Nakamura, Y.; Laks, D. R.; Mischel, P. S.; Viapiano, M.; Kornblum, H. I., Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. Neuro-oncology, 2011, 13 (6), 622-34.
95. Pandit, B.; Bhat, U. G.; Gartel, A. L., Proteasome inhibitory activity of thiazole antibiotics. Cancer biology & therapy, 2011, 11 (1), 43-7.
96. Bhat, U. G.; Halasi, M.; Gartel, A. L., FoxM1 is a general target for proteasome inhibitors. PloS one, 2009, 4 (8), e6593.
97. Newick, K.; Cunniff, B.; Preston, K.; Held, P.; Arbiser, J.; Pass, H.; Mossman, B.; Shukla, A.; Heintz, N., Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. PloS one, 2012, 7 (6), e39404.
98. Anderson, B.; Hodgkin, D. C.; Viswamitra, M. A., The structure of thiostrepton. Nature, 1970, 225 (5229), 233-5.
99. Hensens, O. D.; Albers-Schonberg, G.; Anderson, B. F., The solution conformation of the peptide antibiotic thiostrepton: a 1H NMR study. J. Antibiotics, 1983, 36 (7), 799-813.
100. Yuzenkova, J.; Delgado, M.; Nechaev, S.; Savalia, D.; Epshtein, V.; Artsimovitch, I.; Mooney, R. A.; Landick, R.; Farias, R. N.; Salomon, R.; Severinov, K., Mutations of bacterial RNA polym-erase leading to resistance to microcin j25. J. Biol. Chem., 2002, 277 (52), 50867-75.
101. Mukhopadhyay, J.; Sineva, E.; Knight, J.; Levy, R. M.; Ebright, R. H., Antibacterial peptide microcin J25 inhibits transcription by binding within and obstructing the RNA polymerase secondary channel. Mol. Cell, 2004, 14 (6), 739-51.
102. Niklison-Chirou, M. V.; Dupuy, F.; Pena, L. B.; Gallego, S. M.; Barreiro-Arcos, M. L.; Avila, C.; Torres-Bugeau, C.; Arcuri, B. E.; Bellomio, A.; Minahk, C.; Morero, R. D., Microcin J25 triggers cy-tochrome c release through irreversible damage of mitochondrial proteins and lipids. Int. J. Biochem. Cell Biol., 2010, 42 (2), 273-81.
103. Niklison Chirou, M.; Bellomio, A.; Dupuy, F.; Arcuri, B.; Minahk, C.; Morero, R., Microcin J25 induces the opening of the mitochon-drial transition pore and cytochrome c release through superoxide generation. The FEBS journal, 2008, 275 (16), 4088-96.
104. Wilson, K. A.; Kalkum, M.; Ottesen, J.; Yuzenkova, J.; Chait, B. T.; Landick, R.; Muir, T.; Severinov, K.; Darst, S. A., Structure of microcin J25, a peptide inhibitor of bacterial RNA polymerase, is a lassoed tail. J. Am. Chem. Soc., 2003, 125 (41), 12475-83.
105. Bayro, M. J.; Mukhopadhyay, J.; Swapna, G. V.; Huang, J. Y.; Ma, L. C.; Sineva, E.; Dawson, P. E.; Montelione, G. T.; Ebright, R. H., Structure of antibacterial peptide microcin J25: a 21-residue lariat protoknot. J. Am. Chem. Soc., 2003, 125 (41), 12382-3.
106. Rintoul, M. R.; de Arcuri, B. F.; Morero, R. D., Effects of the antibiotic peptide microcin J25 on liposomes: role of acyl chain length and negatively charged phospholipid. Biochim. Biophys. Acta, 2000, 1509 (1-2), 65-72.
107. Dupuy, F.; Morero, R., Microcin J25 membrane interaction: selectivity toward gel phase. Biochim. Biophys. Acta, 2011, 1808 (6), 1764-71.
108. Bellomio, A.; Oliveira, R. G.; Maggio, B.; Morero, R. D., Penetration and interactions of the antimicrobial peptide, microcin J25, into uncharged phospholipid monolayers. J. Colloid Interface Sci., 2005, 285 (1), 118-24.
109. Daly, N. L.; Rosengren, K. J.; Craik, D. J., Discovery, structure and biological activities of cyclotides. Adv. Drug Deliv. Rev., 2009, 61 (11), 918-30.
110. Skjeldal, L.; Gran, L.; Sletten, K.; Volkman, B. F., Refined structure and metal binding site of the kalata B1 peptide. Arch. Biochem. Biophys., 2002, 399 (2), 142-8.
111. Saether, O.; Craik, D. J.; Campbell, I. D.; Sletten, K.; Juul, J.; Norman, D. G., Elucidation of the primary and three-dimensional structure of the uterotonic polypeptide kalata B1. Biochemistry, 1995, 34 (13), 4147-58.
112. Gran, L.; Sandberg, F.; Sletten, K., Oldenlandia affinis (R&S) DC. A plant containing uteroactive peptides used in African traditional medicine. J. Ethnopharmacol., 2000, 70 (3), 197-203.
113. Fjellestad-Paulsen, A.; Hoglund, P.; Lundin, S.; Paulsen, O., Phar-macokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin. Endocrinol. (Oxf). 1993, 38 (2), 177-82.
114. Kenakin, T., Quantifying Biological Activity in Chemical Terms: A Pharmacology Primer to Describe Drug Effect. ACS Chem. Biol., 2009.
115. Greenwood, K. P.; Daly, N. L.; Brown, D. L.; Stow, J. L.; Craik, D. J., The cyclic cystine knot miniprotein MCoTI-II is internalized into cells by macropinocytosis. Int. J. Biochem. Cell Biol., 2007, 39 (12), 2252-64.
116. Wadia, J. S.; Stan, R. V.; Dowdy, S. F., Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med., 2004, 10 (3), 310-5.
117. Shenkarev, Z. O.; Nadezhdin, K. D.; Sobol, V. A.; Sobol, A. G.; Skjeldal, L.; Arseniev, A. S., Conformation and mode of membrane interaction in cyclotides. Spatial structure of kalata B1 bound to a dodecylphosphocholine micelle. The FEBS journal, 2006, 273 (12), 2658-72.
118. Wang, C. K.; Colgrave, M. L.; Ireland, D. C.; Kaas, Q.; Craik, D. J., Despite a conserved cystine knot motif, different cyclotides have different membrane binding modes. Biophys. J., 2009, 97 (5), 1471-81.
119. Chan, L. Y.; Gunasekera, S.; Henriques, S. T.; Worth, N. F.; Le, S. J.; Clark, R. J.; Campbell, J. H.; Craik, D. J.; Daly, N. L., Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds. Blood, 2011, 118 (25), 6709-17.
120. Gunasekera, S.; Foley, F. M.; Clark, R. J.; Sando, L.; Fabri, L. J.; Craik, D. J.; Daly, N. L., Engineering stabilized vascular endothe-lial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides. J. Med. Chem., 2008, 51 (24), 7697-704.
121. Wong, C. T.; Rowlands, D. K.; Wong, C. H.; Lo, T. W.; Nguyen, G. K.; Li, H. Y.; Tam, J. P., Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew. Chem., 2012, 51 (23), 5620-4.
122. Kennedy, A. R., The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am. J. Clin. Nutr., 1998, 68 (6 Suppl), 1406S-1412S.
123. Voss, R. H.; Ermler, U.; Essen, L. O.; Wenzl, G.; Kim, Y. M.; Flecker, P., Crystal structure of the bifunctional soybean Bowman-Birk inhibitor at 0.28-nm resolution. Structural peculiarities in a folded protein conformation. Eur. J. Biochem., 1996, 242 (1), 122-31.
124. Park, E. Y.; Kim, J. A.; Kim, H. W.; Kim, Y. S.; Song, H. K., Crystal structure of the Bowman-Birk inhibitor from barley seeds in ternary complex with porcine trypsin. J. Mol. Biol., 2004, 343 (1), 173-86.
125. Yavelow, J.; Collins, M.; Birk, Y.; Troll, W.; Kennedy, A. R., Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro. Proc. Natl. Acad. Sci. U. S. A., 1985, 82 (16), 5395-9.
126. Weed, H. G.; McGandy, R. B.; Kennedy, A. R., Protection against dimethylhydrazine-induced adenomatous tumors of the mouse colon by the dietary addition of an extract of soybeans containing the Bowman-Birk protease inhibitor. Carcinogenesis, 1985, 6 (8), 1239-41.
127. Billings, P. C.; St Clair, W. H.; Maki, P. A.; Kennedy, A. R., Distribution of the Bowman Birk protease inhibitor in mice following oral administration. Cancer Lett., 1992, 62 (3), 191-7.
128. Saeki, T.; Ueda, K.; Tanigawara, Y.; Hori, R.; Komano, T., Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem., 1993, 268 (9), 6077-80.
129. Sharom, F. J.; Lu, P.; Liu, R.; Yu, X., Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. Biochem. J., 1998, 333 (Pt 3), 621-30.
130. Ptachcinski, R. J.; Venkataramanan, R.; Burckart, G. J., Clinical pharmacokinetics of cyclosporin. Clin. Pharmacokinet., 1986, 11 (2), 107-32.
131. Lown, K. S.; Mayo, R. R.; Leichtman, A. B.; Hsiao, H. L.; Tur-geon, D. K.; Schmiedlin-Ren, P.; Brown, M. B.; Guo, W.; Rossi, S. J.; Benet, L. Z.; Watkins, P. B., Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cy-closporine. Clin. Pharmacol. Ther., 1997, 62 (3), 248-60.
132. Wacher, V. J.; Silverman, J. A.; Zhang, Y.; Benet, L. Z., Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 1998, 87 (11), 1322-30.
133. Koch, K.; Afonin, S.; Ieronimo, M.; Berditsch, M.; Ulrich, A. S., Solid-state (19)F-NMR of peptides in native membranes. Top. Curr. Chem., 2012, 306, 89-118.
134. Oren, Z.; Shai, Y., Cyclization of a cytolytic amphipathic alpha-helical peptide and its diastereomer: effect on structure, interaction with model membranes, and biological function. Biochemistry, 2000, 39 (20), 6103-14.
135. Tomasinsig, L.; Skerlavaj, B.; Papo, N.; Giabbai, B.; Shai, Y.; Zanetti, M., Mechanistic and functional studies of the interaction of a proline-rich antimicrobial peptide with mammalian cells. J. Biol. Chem., 2006, 281 (1), 383-91.
136. Dancik, V.; Seiler, K. P.; Young, D. W.; Schreiber, S. L.; Clemons, P. A., Distinct biological network properties between the targets of natural products and disease genes. J. Am. Chem. Soc., 2010, 132 (27), 9259-61.